Wednesday, July 8, 2026

Drug profile · INN

clemastine fumarate

clemastine fumarate (TAVIST) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — clemastine fumarate
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.89

Quick answer

clemastine fumarate (TAVIST) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN clemastine fumarate
Brand TAVIST
Mechanism Histamine H1 receptor antagonist
Target Histamine H1 receptor
Route ORAL
Formulation SYRUP

Mechanism of action

Histamine H1 receptor antagonist

Primary target: Histamine H1 receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. azelastine hydrochloride Histamine H1 receptor antagonist
  2. brompheniramine maleate Histamine H1 receptor antagonist
  3. carbinoxamine maleate Histamine H1 receptor antagonist
  4. cetirizine hydrochloride Histamine H1 receptor antagonist
  5. chlorpheniramine maleate Histamine H1 receptor antagonist
  6. cyproheptadine hydrochloride Histamine H1 receptor antagonist

Frequently asked questions

What is clemastine fumarate?

clemastine fumarate (TAVIST) is a histamine h1 receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for clemastine fumarate?

TAVIST is a marketed brand name for clemastine fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of clemastine fumarate?

clemastine fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.